---  
layout: startup_page  
title: "Candid Therapeutics"  
id: "candidrx.com"  
permalink: "/candidtherapeuticscandidrx.com09092024/"  
website: "https://www.candidrx.com"  
funding_round: "Series A"  
funding_amount: "$370M"  
investors: "Venrock Healthcare Capital Partners, Fairmount, TCGX, venBio Partners, Foresite Capital, Third Rock Ventures, Fidelity Management & Research Company, Samsara BioCapital, Qiming Venture Partners USA, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Innovation Fund, Soleus Capital"  
about: "Candid Therapeutics is a biotechnology company developing T-cell engager (TCE) antibodies to treat autoimmune diseases. The company's lead candidates, CND106 and CND261, have shown promise in clinical trials and target specific B lymphocyte cell populations. Candid aims to be the first to bring these novel TCE therapies to market for autoimmune conditions."  
markets: "Biotechnology, Immunotherapy, Autoimmune Diseases"  
hq: "San Diego, California, United States"  
founded_year: "2024"  
linkedin: "https://www.linkedin.com/company/candidrx"  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/candid-therapeutics"  
pitchbook: "https://pitchbook.com/profiles/company/608777-74"  

date_display: "09-Sep-2024"  
date: "2024-09-09"

# SEO Optimization  
meta_title: "Candid Therapeutics - Series A Funding ($370M)"  
meta_description: "Candid Therapeutics, Candid Therapeutics is a biotechnology company developing T-cell engager (TCE) antibodies to treat autoimmune diseases. The company's lead candidates,..."  
meta_keywords: "Candid Therapeutics, Biotechnology, Immunotherapy, Autoimmune Diseases, Series A funding"  
canonical_url: "https://startup.projectstartups.com/candidtherapeuticscandidrx.com09092024/"  
---